- Home
- CRMD vs DCTH Comparison
CRMD vs DCTH Comparison
Compare CRMD & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- DCTH
- Stock Information
- Founded
- CRMD 2006
- DCTH 1988
- Country
- CRMD United States
- DCTH United States
- Employees
- CRMD N/A
- DCTH N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- CRMD Health Care
- DCTH Health Care
- Exchange
- CRMD Nasdaq
- DCTH Nasdaq
- Market Cap
- CRMD 464.7M
- DCTH 518.0M
- IPO Year
- CRMD 2010
- DCTH N/A
- Fundamental
- Price
- CRMD $8.50
- DCTH $11.87
- Analyst Decision
- CRMD Strong Buy
- DCTH Strong Buy
- Analyst Count
- CRMD 6
- DCTH 4
- Target Price
- CRMD $14.50
- DCTH $22.75
- AVG Volume (30 Days)
- CRMD 2.6M
- DCTH 458.0K
- Earning Date
- CRMD 05-08-2025
- DCTH 05-13-2025
- Dividend Yield
- CRMD N/A
- DCTH N/A
- EPS Growth
- CRMD N/A
- DCTH N/A
- EPS
- CRMD N/A
- DCTH N/A
- Revenue
- CRMD $43,472,170.00
- DCTH $37,205,000.00
- Revenue This Year
- CRMD $207.65
- DCTH $128.78
- Revenue Next Year
- CRMD $50.13
- DCTH $54.07
- P/E Ratio
- CRMD N/A
- DCTH N/A
- Revenue Growth
- CRMD N/A
- DCTH 1701.69
- 52 Week Low
- CRMD $3.61
- DCTH $5.04
- 52 Week High
- CRMD $13.85
- DCTH $16.97
- Technical
- Relative Strength Index (RSI)
- CRMD 57.04
- DCTH 47.65
- Support Level
- CRMD $6.32
- DCTH $11.05
- Resistance Level
- CRMD $7.71
- DCTH $11.84
- Average True Range (ATR)
- CRMD 0.49
- DCTH 0.97
- MACD
- CRMD 0.32
- DCTH 0.09
- Stochastic Oscillator
- CRMD 97.64
- DCTH 57.89
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.